Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $496.42 USD
Change Today -17.08 / -3.33%
Volume 899.2K
REGN On Other Exchanges
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

George D. Yancopoulos M.D., Ph.D.

Chief Scientific Officer, Director, Member of Technology Committee and President of Regeneron Research Laboratories,Regeneron Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 24 board members in 2 different organizations across 2 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. George D. Yancopoulos, M.D., Ph.D. has been the Chief Scientific Officer and Executive Vice President of Regeneron Pharmaceuticals, Inc. since December 2000. Dr. Yancopoulos has been the President of Regeneron Research Laboratories, a subsidiary of Regeneron Pharmaceuticals, Inc. since December 2000. He served as the Senior Vice President, Research of Regeneron Research Laboratories, a position he held since June 1997, and Chief Scientific Officer, a position he ...

Read Full Background

Corporate Headquarters*

777 Old Saw Mill River Road
Tarrytown, New York 10591

United States

Phone: 914-847-7000
Fax: --

Board Members Memberships*

Chief Scientific Officer, Director, Member of Technology Committee and President of Regeneron Research Laboratories


Columbia University
Columbia University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$2,731,540

Stock Options*

All Other Compensation$30,525
Exercised Options198,447
Exercised Options Value$59,168,380
Exercisable Options1,839,747
Exercisable Options Value$673,629,469
Unexercisable Options484,657
Unexercisable Options Value$65,092,929
Total Value of Options$797,890,777
Total Number of Options2,522,851

Total Compensation*

Total Annual Cash Compensation$2,762,065
Total Short Term Compensation$2,731,540
Other Long Term Compensation$30,525
Total Calculated Compensation$35,506,811
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $496.42 USD -17.08


Jean-Jacques Bienaime MBAChairman and Chief Executive Officer
BioMarin Pharmaceutical Inc.
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
Herve Hoppenot Chief Executive Officer, President, Director and Member of Non-Management Stock Option Committee
Incyte Corporation
Nobuo Hanai Ph.D.Chief Executive Officer, President and Representative Director
Kyowa Hakko Kirin Co., Ltd.
Jean-Christophe Tellier Chief Executive Officer and Executive Director
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at